(Q43647206)

English

Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study

scientific article published on 9 June 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 November 2017

Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study (English)

1 reference

Europe PubMed Central

25 November 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

circulatory system

1 reference

based on heuristic

inferred from title

Christian Torp-Pedersen

7

object named as

C Torp-Pedersen

1 reference

Europe PubMed Central

25 November 2017

9

object named as

L Køber

1 reference

Europe PubMed Central

25 November 2017

Gunnar Hilmar Gislason

8

object named as

G Gislason

1 reference

Europe PubMed Central

25 November 2017

author name string

U M Mogensen

1

1 reference

Europe PubMed Central

25 November 2017

C Andersson

2

1 reference

Europe PubMed Central

25 November 2017

E L Fosbøl

3

1 reference

Europe PubMed Central

25 November 2017

T K Schramm

4

1 reference

Europe PubMed Central

25 November 2017

A Vaag

5

1 reference

Europe PubMed Central

25 November 2017

N M Scheller

6

1 reference

Europe PubMed Central

25 November 2017

publication date

9 June 2014

1 reference

Europe PubMed Central

25 November 2017

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

25 November 2017

16

1 reference

Europe PubMed Central

25 November 2017

10

1 reference

Europe PubMed Central

25 November 2017

1001-1008

1 reference

Europe PubMed Central

25 November 2017

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

Cardiovascular biology of the incretin system

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

Incretin-based therapies and cardiovascular risk

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

Cardiovascular effects of gliptins

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients--a nationwide study

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

Risk of cancer in patients using glucose-lowering agents: a nationwide cohort study of 3.6 million people

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

Accuracy of a heart failure diagnosis in administrative registers

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12314

21 January 2018

Sulphonylurea monotherapy for patients with type 2 diabetes mellitus

1 reference

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD009008.PUB2

12 January 2024

Identifiers

10.1111/DOM.12314

1 reference

Europe PubMed Central

25 November 2017

1 reference

Europe PubMed Central

25 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43647206&oldid=2102303121"